Marbocare Flavour (1.3 - 2.5 kg)

10 x 10 pc

Tablet

Active substance

Marbofloxacin : 5 mg

ATC code

QJ01MA93 Marbofloxacin

QJ01MA Fluoroquinolones

QJ01M Quinolone and quinoxaline antibacterials

QJ01 Antibacterials for systemic use

QJ Antiinfectives for systemic use

Species

Dogs and Cats

Indications

Marbofloxacin is indicated in the treatment of the following infections caused by susceptible strains of organisms (see section 5.1);

Dogs

Skin and soft tissue infections (skinfold pyoderma, impetigo, folliculitis, furunculosis, cellulitis)
Urinary tract infections (UTI) associated or not with prostatitis or epididymitis
Respiratory tract infections

Cats

Skin and soft tissue infections (wounds, abscesses, phlegmons)
Upper respiratory tract infections

Dose to be administered and administration route

For oral administration.

The recommended dose rate is 2 mg/kg/day in a single daily administration (see table below).

Body Weight	Tablets
1.3 – 2.5 kg	1
2.6 – 5.0 kg	2

To ensure a correct dosage body weight should be determined as accurately as possible to avoid underdosing.

DOGS:

In skin and soft tissue infections, treatment duration is at least 5 days.
Depending on the course of the disease, it may be extended up to 40 days.
In urinary tract infections, treatment duration is at least 10 days. Depending on the course of the disease, it may be extended up to 28 days.
In respiratory infections, treatment duration is at least 7 days and depending on the course of the disease, it may be extended up to 21 days.

CATS:

For skin and soft tissue infections (wounds, abscesses, phlegmons) treatment duration is 3 to 5days.
For upper respiratory infections treatment duration is 5 days.

Adverse reactions

Mild side effects such as vomiting, softening of faeces, modification of thirst or transient increase in activity may very rarely occur. These signs cease spontaneously after treatment and do not necessitate cessation of treatment.

The frequency of adverse reactions is defined using the following convention:

- Very common (more than 1 in 10 animals treated displaying adverse reaction(s))

- Common (more than 1 but less than 10 animals in 100 animals treated)

- Uncommon (more than 1 but less than 10 animals in 1,000 animals treated)

- Rare (more than 1 but less than 10 animals in 10,000 animals treated)

- Very rare (less than 1 animal in 10,000 animals treated, including isolated reports)